Stock ATXS ASTRIA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Astria Therapeutics, Inc.

Equities

ATXS

US04635X1028

Biotechnology & Medical Research

Real-time Estimate Cboe BZX
Other stock markets
 12:08:55 01/05/2024 am IST 		5-day change 1st Jan Change
9.225 USD +0.82% Intraday chart for Astria Therapeutics, Inc. -4.72% +19.60%
23/04 HC Wainwright Cuts Astria Therapeutics' Price Target to $16 From $18, Maintains Buy Rating MT
09/04 Astria Therapeutics, Inc. Appoints Sunil Agarwal to the Board of Directors and Member of the Science and Technology Committee CI

Business Summary

Astria Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for allergic and immunological diseases. The Company's lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema (HAE), a rare, debilitating and potentially life-threatening disease. Its second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis (AD). The Company owns two patent families directed to STAR-0215. The first patent family is directed to the composition of matter of its product candidate STAR-0215 and its use in treating various plasma kallikrein associated disorders including HAE. In the second patent family, the Company owns one International (PCT) patent application directed to methods of treating various plasma-kallikrein associated disorders, including HAE, with specific dosing regimens of the STAR-0215 antibody.

Number of employees: 59

Managers

Managers TitleAgeSince
Jill Milne FOU
 Founder 56 26/08/26
Noah Clauser DFI
 Director of Finance/CFO 51 01/11/01
Christopher J Morabito CTO
 Chief Tech/Sci/R&D Officer - 15/22/15
John Ruesch PRN
 Corporate Officer/Principal - 17/23/17
Keri McGrail HRO
 Human Resources Officer - 01/21/01
Andrew Komjathy PRN
 Corporate Officer/Principal 61 25/19/25
Ben Harshbarger LAW
 General Counsel 55 12/20/12
Andrea Matthews PRN
 Corporate Officer/Principal - 01/14/01

Members of the board

Members of the board TitleAgeSince
Ken Bate CHM
 Chairman 73 01/14/01
Gregg Lapointe BRD
 Director/Board Member 65 04/19/04
Michael Kishbauch BRD
 Director/Board Member 75 05/16/05
Jonathan Violin BRD
 Director/Board Member 49 28/21/28
Jill Milne FOU
 Founder 56 26/08/26
Hugh Cole BRD
 Director/Board Member 59 26/19/26
Joanne Beck BRD
 Director/Board Member 63 14/19/14
Frederick Callori BRD
 Director/Board Member 56 28/21/28

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 54,913,061 48,159,943 ( 87.70 %) 0 87.70 %
Stock B 0 31,107 0 0

Shareholders

NameEquities%Valuation
Perceptive Advisors LLC
11.81 %
6,485,420 11.81 % 91 M $
Fidelity Management & Research Co. LLC
8.748 %
4,803,025 8.748 % 68 M $
RA Capital Management LP
8.038 %
4,413,150 8.038 % 62 M $
TCG Crossover Management LLC
7.958 %
4,368,928 7.958 % 61 M $
Perceptive Advisors LLC
7.293 %
4,004,070 7.293 % 56 M $
Fairmount Funds Management LLC
6.473 %
3,554,129 6.473 % 50 M $
Venrock Associates
5.875 %
3,225,806 5.875 % 45 M $
Vivo Capital LLC
4.242 %
2,329,027 4.242 % 33 M $
BlackRock Advisors LLC
3.824 %
2,099,310 3.824 % 30 M $
Vanguard Fiduciary Trust Co.
3.744 %
2,055,707 3.744 % 29 M $
NameEquities%Valuation
Perceptive Advisors LLC
32.85 %
30,018 32.85 % 422 503 $

Company contact information

Astria Therapeutics, Inc.

75 State Street Suite 1400

02109, Boston

+

http://www.astriatx.com
address Astria Therapeutics, Inc.(ATXS)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
9.15 USD
Average target price
25.29 USD
Spread / Average Target
+176.35%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ASTRIA THERAPEUTICS, INC. Stock Astria Therapeutics, Inc.
+19.60% 502M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-3.24% 102B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+1.68% 96.29B
ARGENX SE Stock argenx SE
+2.13% 22.18B
BIONTECH SE Stock BioNTech SE
-15.68% 21.2B
GENMAB A/S Stock Genmab A/S
-9.21% 18.31B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.98% 17.38B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.75% 16.36B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.83% 13.97B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.79% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ATXS Stock
  4. Company Astria Therapeutics, Inc.